US · Healthcare · Biotechnology
EPS came in at -0.49 against a street estimate of -0.38 — a miss of 28.9%.
Analysts rate Enliven Therapeutics Inc. a strong buy (14 buy, 0 hold, 0 sell out of 14) with an average price target of $73.67.
| Fund | Stake |
|---|---|
| FMR Inc | 13.68% |
| Orbimed Advisors LLC | 9.25% |
| Polar Capital Holdings PLC | 8.78% |
| BlackRock Inc | 5.95% |
| Vestal Point Capital LP | 5.46% |
| COMMODORE CAPITAL LP | 4.47% |
| T. Rowe Price Associates, Inc. | 3.96% |
| Vanguard Capital Management, LLC | 3.51% |
| Document | Date |
|---|---|
| Board / officer change · Q4 2026 HEADLINE NUMBERS • Enliven Therapeutics appointed Kristine Ball to its board of directors on October 14, 2026. • The board expanded from seven to ei | 2026-10-14 |
| Quarterly report · Q2 2026 ENLIVEN THERAPEUTICS, INC. – Q2 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Cash & Marketable Securities: $895.2 million as of June 30, 2026 (up from | 2026-08-05 |
| Results announced · Q3 2026 ENLIVEN THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: $895.2 million in cash, cash equivalents and marketable sec | 2026-08-05 |
| Material agreement · Q2 2026 ENLIVEN THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company conducting public offering of 8,933,334 shares of common stock at $37.50 per sha | 2026-06-12 |
| Reg FD disclosure · Q2 2026 ENLIVEN THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • 161 patients enrolled in Phase 1 ENABLE trial as of March 10, 2026 cutoff date across do | 2026-06-11 |
| Charter / bylaws change · Q2 2026 ENLIVEN THERAPEUTICS, INC. — 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting of Stockholders held June 9, 2026 • Authorized common stock shares increa | 2026-06-10 |
| Quarterly report · Q1 2026 ENLIVEN THERAPEUTICS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash and Marketable Securities: $452.4 million as of March 31, 2026 (down from | 2026-05-07 |
| Proxy statement · Q2 2026 ENLIVEN THERAPEUTICS, INC. — 2026 PROXY SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect two Class III directors to serve until the | 2026-04-27 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Enliven Therapeutics Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.